1180 SEMINOLE TRAIL, CHARLOTTESVILLE, VA
Restricted Stock Awards Granted to Executive Officers at Adial Pharmaceuticals
Reports 2025 Fiscal Year Financial Results and Provides Business Update
Press Release Issued By Adial Pharmaceuticals, Inc., March 3, 2026
Regains Full Compliance with Nasdaq Listing Requirement
Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
Director Resignation - James W. Newman, Jr. Steps Down from Board
Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Reports Third Quarter 2025 Financial Results and Provides Business Update
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
PRER14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Definitive Revised Proxy Statement
Correspondence
Submission Upload